NCT03846583 2020-10-23
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
Phase 1 Withdrawn
Clinical Trials
7 trialsNCT04088032 2020-07-16
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
Phase EARLY_PHASE1 Withdrawn
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT00080613 2013-07-10
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01612728 2013-02-12
AIA
Baylor Breast Care Center
Phase 2 Withdrawn
NCT00945360 2012-07-13
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
American University of Beirut Medical Center
Phase 1 Withdrawn
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn